Mitigating Blue-Light Risk in Display-Based Digital Therapeutics: A Practical Framework to Support Clinical Efficacy.

PAPER pubmed Journal of clinical medicine 2026 Review Effect: harm Evidence: Insufficient

Read original paper → DOI: 10.3390/jcm15041371 PMID: 41753059 Evidence Lab

Abstract

Display-driven optical stimuli underpin a major class of clinically validated digital therapeutics (DTx) now expanding from neuropsychiatric disorders to chronic diseases. The display's optical characteristics-spectral power distribution, luminance, contrast, and temporal modulation-therefore define the delivered dose of these software-based interventions. In this context, blue-rich emission in the 450-480 nm band, particularly with evening exposure, can suppress melatonin via melanopsin-mediated intrinsically photo-sensitive retinal ganglion cell (ipRGC) pathways and perturb circadian timing, potentially attenuating therapeutic efficacy. This review summarizes clinical evidence for display-enabled DTx across major indications and synthesizes mechanistic and experimental data linking blue light to sleep and circadian disruption, with downstream mood, cognitive, cardiovascular, and metabolic effects, as well as increased risk of cancer and skin damage. This review distinguishes wavelength-dependent hazards by separating retinal photochemical risk in the roughly 415-450 nm range from circadian-disruptive melanopic effects in the 450-480 nm range, informing spectrum optimization for therapeutic use. It then synthesizes mitigation strategies spanning display emitter spectrum engineering, optical filtering or conversion films, and software controls such as color temperature tuning, high-frequency dimming, metameric spectrum design, and personalized circadian lighting. The review concludes with design, prescription, and standards considerations to align display output with therapeutic intent.

AI evidence extraction

At a glance

Study type

Review

Effect direction

harm

Population

—

Sample size

—

Exposure

other display-based digital therapeutics (screens/displays)

Evidence strength

Insufficient

Confidence: 66% · Peer-reviewed: yes

Main findings

The review states that blue-rich display emission in the 450–480 nm band, particularly with evening exposure, can suppress melatonin via melanopsin-mediated ipRGC pathways and perturb circadian timing, potentially attenuating digital therapeutic efficacy. It distinguishes retinal photochemical risk (~415–450 nm) from circadian-disruptive melanopic effects (450–480 nm) and summarizes mitigation strategies including spectrum engineering, filtering/films, and software controls (e.g., color temperature tuning, high-frequency dimming, metameric spectrum design, personalized circadian lighting).

Outcomes measured

melatonin suppression
circadian timing disruption
sleep disruption
mood effects
cognitive effects
cardiovascular effects
metabolic effects
cancer risk
skin damage
retinal photochemical risk

View raw extracted JSON

{
    "study_type": "review",
    "exposure": {
        "band": "other",
        "source": "display-based digital therapeutics (screens/displays)",
        "frequency_mhz": null,
        "sar_wkg": null,
        "duration": null
    },
    "population": null,
    "sample_size": null,
    "outcomes": [
        "melatonin suppression",
        "circadian timing disruption",
        "sleep disruption",
        "mood effects",
        "cognitive effects",
        "cardiovascular effects",
        "metabolic effects",
        "cancer risk",
        "skin damage",
        "retinal photochemical risk"
    ],
    "main_findings": "The review states that blue-rich display emission in the 450–480 nm band, particularly with evening exposure, can suppress melatonin via melanopsin-mediated ipRGC pathways and perturb circadian timing, potentially attenuating digital therapeutic efficacy. It distinguishes retinal photochemical risk (~415–450 nm) from circadian-disruptive melanopic effects (450–480 nm) and summarizes mitigation strategies including spectrum engineering, filtering/films, and software controls (e.g., color temperature tuning, high-frequency dimming, metameric spectrum design, personalized circadian lighting).",
    "effect_direction": "harm",
    "limitations": [],
    "evidence_strength": "insufficient",
    "confidence": 0.66000000000000003108624468950438313186168670654296875,
    "peer_reviewed_likely": "yes",
    "keywords": [
        "digital therapeutics",
        "display",
        "blue light",
        "450-480 nm",
        "melatonin",
        "melanopsin",
        "ipRGC",
        "circadian disruption",
        "sleep",
        "retinal photochemical risk",
        "spectrum optimization",
        "optical filtering",
        "software controls",
        "dimming",
        "color temperature"
    ],
    "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

No comments yet.